Daré Bioscience, Inc.
NASDAQ:DARE
2.97 (USD) • At close May 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.01 | 2.808 | 10 | 0 | 0 | 0 | 0 | 0 | 0.766 | 0 | 0.08 | 0.006 | 0.625 | 0.305 |
| Cost of Revenue
| 0 | 0.038 | 0.048 | 0.026 | 0.043 | 0.011 | 0.002 | 0 | 0.4 | 0.192 | 0 | 0 | 0 | 0.363 |
| Gross Profit
| 0.01 | 2.77 | 9.952 | -0.026 | -0.043 | -0.011 | -0.002 | 0 | 0.366 | -0.192 | 0.08 | 0.006 | 0.625 | -0.058 |
| Gross Profit Ratio
| 1 | 0.986 | 0.995 | 0 | 0 | 0 | 0 | 0 | 0.478 | 0 | 1 | 1 | 1 | -0.19 |
| Reseach & Development Expenses
| 14.205 | 21.538 | 30.042 | 30.618 | 20.769 | 8.546 | 6.414 | 0.985 | 27.565 | 25.948 | 11.772 | 9.7 | 15.807 | 13.485 |
| General & Administrative Expenses
| 9,156.061 | 12.11 | 11.243 | 8.451 | 6.633 | 5.799 | 5.281 | 2.705 | 10.355 | 11.224 | 8.587 | 6.166 | 6.393 | 0 |
| Selling & Marketing Expenses
| -9,146.905 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 9.156 | 12.11 | 11.243 | 8.451 | 6.633 | 5.799 | 5.281 | 2.705 | 10.355 | 11.224 | 8.587 | 6.166 | 6.393 | 5.335 |
| Other Expenses
| 0 | 0 | 0.1 | 0.003 | 0.002 | 0.081 | 0.143 | 7,490.886 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 22.848 | 33.609 | 41.385 | 39.069 | 27.402 | 14.345 | 11.695 | 3.69 | 37.92 | 37.172 | 20.359 | 15.866 | 22.2 | 18.82 |
| Operating Income
| -23.451 | -30.84 | -31.385 | -39.069 | -27.402 | -14.345 | -16.882 | -11.18 | -37.154 | -37.172 | -20.279 | -15.86 | -21.575 | -18.878 |
| Operating Income Ratio
| -2,396.922 | -10.983 | -3.139 | 0 | 0 | 0 | 0 | 0 | -48.504 | 0 | -253.488 | -2,643.333 | -34.52 | -61.895 |
| Total Other Income Expenses Net
| -4,030.148 | 0.678 | 0.438 | 0.372 | 0.002 | 0.081 | 0.143 | -0.323 | -2.151 | -2.422 | -3.063 | -1.283 | -0.526 | -0.064 |
| Income Before Tax
| -4,053.599 | -30.161 | -30.948 | -38.696 | -27.401 | -14.264 | -16.739 | -11.503 | -39.305 | -39.594 | -23.342 | -17.143 | -22.101 | -18.942 |
| Income Before Tax Ratio
| -414,308.974 | -10.742 | -3.095 | 0 | 0 | 0 | 0 | 0 | -51.312 | 0 | -291.775 | -2,857.167 | -35.362 | -62.105 |
| Income Tax Expense
| -4,049.545 | 0 | -437.75 | -0.37 | -0.163 | -0.161 | 10.232 | -7.168 | 0.086 | 0.01 | 1.083 | 1.487 | 0.567 | 0 |
| Net Income
| -4.054 | -30.161 | -30.948 | -38.326 | -27.401 | -14.264 | -26.97 | -11.503 | -39.305 | -39.594 | -23.342 | -17.143 | -22.101 | -19.563 |
| Net Income Ratio
| -414.309 | -10.742 | -3.095 | 0 | 0 | 0 | 0 | 0 | -51.312 | 0 | -291.775 | -2,857.167 | -35.362 | -64.141 |
| EPS
| -0.48 | -4.15 | -4.39 | -7.52 | -10.93 | -10.99 | -30.16 | -3.56 | -14.18 | -15.57 | -16.04 | -9.02 | -280.83 | -267.41 |
| EPS Diluted
| -0.48 | -4.15 | -4.39 | -7.52 | -10.93 | -10.99 | -30.16 | -3.56 | -14.18 | -15.57 | -16.04 | -9.02 | -280.83 | -267.41 |
| EBITDA
| -3.54 | -30.902 | -31.361 | -39.042 | -27.359 | -14.334 | -11.692 | -11.18 | -36.807 | -36.97 | -22.133 | -15.459 | -21.188 | -18.553 |
| EBITDA Ratio
| -361.842 | -11.005 | -3.136 | 0 | 0 | 0 | 0 | 0 | -48.051 | 0 | -276.663 | -2,576.5 | -33.901 | -60.83 |